J Korean Diabetes.  2024 Jun;25(2):89-92. 10.4093/jkd.2024.25.2.89.

2024 Policy Revision for Support of Type 1 Diabetes Mellitus Patients

• Yoo JH

• KMID: 2556759
• DOI: http://doi.org/10.4093/jkd.2024.25.2.89

Abstract

Type 1 diabetes mellitus is a condition where the pancreas beta cells are destroyed due to autoimmune mechanisms or viral infections, resulting in the inability to produce insulin. The Korean government implements various support programs to aid in the health management of type 1 diabetes patients. To address some shortcomings and adapt to diverse needs arising from advancements in diabetes management device technology, related policies were revised starting on February 26, 2024. Key updates include application of the criteria for continuous glucose monitoring system sensors to users of sensor-augmented pumps and establishing consumable material subsidies for users of closed-loop insulin pumps who are younger than 19 years. Support amounts vary based on the type of insulin pump, which vary by application. Additionally, to enhance diabetes education for pediatric and adolescent patients and their families, insulin pump education is newly introduced, along with an expansion of educational counseling sessions. These policies may further aid in patients’ blood glucose management, with hopes for continued expansion of support in the future.

Keyword

Diabetes mellitus, type 1; Education; Equipment and supplies; Health policy; Republic of Korea

Reference

1.Atkinson MA., Eisenbarth GS., Michels AW. Type 1 diabetes. Lancet. 2014. 383:69–82.

2.Shin CH. Type 1 diabetes mellitus. Korean J Pediatr. 2002. 45:1181–91.

3.Kim JH., Lee CG., Lee YA., Yang SW., Shin CH. Increasing incidence of type 1 diabetes among Korean children and adolescents: analysis of data from a nationwide registry in Korea. Pediatr Diabetes. 2016. 17:519–24.

4.American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes-2021. Diabetes Care. 2021. 44(Suppl 1):S85–99.

5.Korean Diabetes Association. Clinical practice guidelines for diabetes. 8th ed. Seoul: Korean Diabetes Association;2023.

6.Ministry of Health and Welfare. Available from: https://www.mohw.go.kr/board.es?mid=a10409020000&bid=0026&act=view&list_no=1480389&tag=&nPage=1 (updated 2024 Feb 23).

7.Health Insurance Review and Assessment Service (HIRA). Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brd-ScnBltNo=4&brdBltNo=10743&pageIndex=1&pageIn-dex2=1 (updated 2024 Feb 21).

8.Cho MK., Kim MY. Influencing factors on quality of life in parents with type 1 diabetes children. Crisisonomy. 2021. 17:137–47.

9.American Diabetes Association (ADA). Introduction: standards of medical care in diabetes-2018. Diabetes Care. 2018. 41(Suppl 1):S1–2.

10.Sherr JL., Schoelwer M., Dos Santos TJ., Reddy L., Biester T., Galderisi A, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: insulin delivery. Pediatr Diabetes. 2022. 23:1406–31.

11.Tauschmann M., Forlenza G., Hood K., Cardona-Hernan-dez R., Giani E., Hendrieckx C, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring. Pediatr Diabetes. 2022. 23:1390–405.